Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 80,000 shares at $73.64 ($6.0M) on 2026-04-09, disclosed to the SEC on 2026-04-13.
Scheduled sale ($6.0M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $73.64 | 7,072 | $521K | 8.7% |
| 2 | $73.64 | 7,200 | $530K | 8.9% |
| 3 | $74.57 | 5,128 | $382K | 6.4% |
| 4 | $74.60 | 5,300 | $395K | 6.6% |
| 5 | $75.53 | 7,800 | $589K | 9.9% |
| 6 | $75.55 | 7,500 |
| $567K |
| 9.5% |
| 7 | $74.60 | 20,000 | $1.5M | 25.0% |
| 8 | $74.60 | 20,000 | $1.5M | 25.0% |
| Total | $74.61 avg | 80,000 | $6.0M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |